Skip Navigation
Skip to contents

대한신장학회


간행물 검색

현재 페이지 경로
  • HOME
  • 간행물
  • 간행물 검색
논문분류 춘계학술대회 초록집
제목 The oxidative inhibitor IM156 suppresses B cell activation by regulating mitochondrial membrane potential and contributes to the mitigation of systemic lupus erythematosus
저자 Joo Sung Shim, Eun Jee Kim, Lucy Eunju Lee, Joon Ye Kim, Yuri Cho, Hanna Kim, Jieun Kim, Sang-Jun Ha, Jason Jungsik Song, Beom Seok Kim
출판정보 2021; 2021(1):
키워드
초록 Objective: We investigated the in vitro and in vivo effects of IM156 on overactive B cells stimulated by the TLR9 agonist CpG oligodeoxynucleotide (ODN). Using RNA sequencing (RNA-seq), we analyzed the B-cell transcriptome expression, identifying the major molecular pathways affected by IM156 in vivo. We also evaluated the anti-inflammatory effects of IM156 in NZB/W F1 mice. Methods: We demonstrated that CD19+ B cells exhibited higher mitochondrial mass and mitochondrial membrane potential than T cells and were more susceptible to IM156-mediated oxidative phosphorylation (OXPHOS) inhibition (P < 0.01 or P < 0.001; N = 3–6). In vivo, IM156 inhibited OXPHOS, cell cycle progression, plasmablast differentiation, and activation marker levels in ODN-stimulated mouse spleen B cells. Interestingly, IM156 treatment significantly increased overall survival (P < 0.05; N = 3–9) and reduced proteinuria (P < 0.05 or P < 0.01; N = 3–9) in lupus-prone NZB/W F1 mice. Our data indicate that IM156 suppressed the mitochondrial membrane potentials of activated B cells in mice, which contributed to mitigation of lupus activity. Results: IM156 may represent a therapeutic alternative for autoimmune diseases mediated by B cell hyperactivity. Conclusions: Objective: Current treatment strategies for autoimmune diseases, including systemic lupus erythematosus, may not sufficiently control the aberrant metabolism in B cells. To address this concern, we investigated a biguanide derivative, IM156, as a potential regulator for B cell metabolism. Methods: We investigated the in vitro and in vivo effects of IM156 on overactive B cells stimulated by the TLR9 agonist CpG oligodeoxynucleotide (ODN). Using RNA sequencing (RNA-seq), we analyzed the B-cell transcriptome expression, identifying the major molecular pathways affected by IM156 in vivo. We also evaluated the anti-inflammatory effects of IM156 in NZB/W F1 mice. Results: We demonstrated that CD19+ B cells exhibited higher mitochondrial mass and mitochondrial membrane potential than T cells and were more susceptible to IM156-mediated oxidative phosphorylation (OXPHOS) inhibition (P < 0.01 or P < 0.001; N = 3–6). In vivo, IM156 inhibited OXPHOS, cell cycle progression, plasmablast differentiation, and activation marker levels in ODN-stimulated mouse spleen B cells. Interestingly, IM156 treatment significantly increased overall survival (P < 0.05; N = 3–9) and reduced proteinuria (P < 0.05 or P < 0.01; N = 3–9) in lupus-prone NZB/W F1 mice. Our data indicate that IM156 suppressed the mitochondrial membrane potentials of activated B cells in mice, which contributed to mitigation of lupus activity. Conclusions: IM156 may represent a therapeutic alternative for autoimmune diseases mediated by B cell hyperactivity.
원문(PDF) PDF 원문보기
위로가기